CLOSEOUT LETTER

ConMed Corporation August 01, 2016

ConMed Corporation


Department of Health and Human Services
	Food and Drug Administration Denver District Office Building 20 - Denver Federal Center P.O. Box 25087 Denver, Colorado 80225-0087 TELEPHONE: 303-236-3000

August 1, 2016

UPS Overnight

Curt Hartment
President & CEO
ConMed Corporation
525 French Road
Utica, New York 13502

Re: DEN-14-02-WL

Dear Mr. Hartman:

The Food and Drug Administration has completed an evaluation of your firm's corrective actions in response to our Warning Letter DEN-14-02-WL, dated January 29, 2014. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,

/S/

LaTonya M. Mitchell
District Director

cc: Mr. Wilfreda Ruiz-Caban
     Executive Vice President
     ConMed Corporation
     525 French Road
     Utica, New York 13502

Department of Health and Human Services